1346702-52-0

Basic information

• Product Name: Methyl 6-broMo-l-(l- Methylethyl)-lH-indazole-4-carboxylate
• Synonyms: Methyl 6-broMo-l-(l- Methylethyl)-lH-indazole-4-carboxylate;6-Bromo-1-(1-methylethyl)-1H-indazole-4-carboxylic acid methyl ester;Methyl 6-bromo-1-(propan-2-yl)-1H-indazole-4-carboxylate;Methyl 6-bromo-1-isopropyl-1H-indazole-4-carboxylate
• CAS NO: 1346702-52-0
• Molecular Formula: C₁₂H₁₃BrN₂O₂
• Molecular Weight: 297.16
• EINECS: -0
• Mol File: 1346702-52-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 372.9±22.0 °C(Predicted)
• Appearance: /
• Density: 1.50±0.1 g/cm3(Predicted)
• PKA: -0.89±0.30(Predicted)
• CAS DataBase Reference: Methyl 6-broMo-l-(l- Methylethyl)-lH-indazole-4-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 6-broMo-l-(l- Methylethyl)-lH-indazole-4-carboxylate(1346702-52-0)
• EPA Substance Registry System: Methyl 6-broMo-l-(l- Methylethyl)-lH-indazole-4-carboxylate(1346702-52-0)

Safety Data

• Hazardous Substances Data: 1346702-52-0(Hazardous Substances Data)

Usage

General Description

Methyl 6-bromo-1-(1-methylethyl)-1H-indazole-4-carboxylate is a chemical compound with the molecular formula C13H15BrN2O2. It is a yellow solid that is used in the synthesis of pharmaceuticals and other organic compounds. This chemical has been found to have potential therapeutic effects, including anti-inflammatory and analgesic properties. It is often used as a reagent in organic chemistry reactions due to its unique structure and functional groups. Methyl 6-bromo-1-(1-methylethyl)-1H-indazole-4-carboxylate is an important compound in the field of medicinal chemistry and drug development, with potential applications in the treatment of various diseases and conditions.

Upstream product

• 885518-49-0 methyl 6-bromo-1H-indazole-4-carboxylate 
• 75-26-3 isopropyl bromide 
• 75-30-9 2-iodo-propane 
• 107650-20-4 5-bromo-2-methyl-3-nitro-benzoic acid 
• 220514-28-3 5-bromo-2-methyl-3-nitrobenzoic acid methyl ester 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 1000342-11-9 2-methyl-3-amino-5-bromobenzoic acid methyl ester 
• 1346597-55-4 methyl 1-acetyl-6-bromo-1H-indazole-4-carboxylate 

Downstream Products

• 1346704-10-6 N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-phenyl-1H-indazole-4-carboxamide 
• 1346704-20-8 N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[2-(trifluoromethyl)phenyl]-1H-indazole-4-carboxamide 
• 1346704-21-9 6-{4-[(dimethylamino)sulfonyl]phenyl}-N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-1H-indazole-4-carboxamide 
• 1346704-23-1 N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-1-(1-methylethyl)-6-(2-methylphenyl)-1H-indazole-4-carboxamide 
• 1346702-59-7 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-(4-(2-(dimethylamino)ethoxy)phenyl)-1-isopropyl-1H-indazole-4-carboxamide 
• 1346704-12-8 N-[(4,6-dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-6-{4-[(methylamino)sulfonyl]phenyl}-1-(methylethyl)-1H-indazole-4-carboxamide 
• 1346702-54-2 6-bromo-1-(1-methylethyl)-1H-indazole-4-carboxylic acid 
• 1346702-68-8 6-(4-((dimethylamino)methyl)phenyl)-N-((4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide 
• 1347232-05-6 6-{4-[(dimethylamino)methyl]phenyl}-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indazole-4-carboxamide 
• 1346702-88-2 6-{4-[(dimethylamino)methyl]phenyl}-1-(1-methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-1H-indazole-4-carboxamide hydrochloride 
• 1346703-11-4 6-bromo-N-((4-cyclohexyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-1H-indazole-4-carboxamide 
• 1346703-10-3 N-((4-cyclohexyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-6-cyclopropyl-1-isopropyl-1H-indazole-4-carboxamide 
• 1396772-45-4 N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-1-isopropyl-6-(4-(morpholinomethyl)phenyl)-1H-indazole-4-carboxamide 
• 1346704-33-3 GSK343 

Relevant articles and documents

Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA

PARP inhibitors have highly significant effects on BRCA mutant cells, allowing targeted therapy of triple-negative breast cancer (TNBC). However, some TBNC patients lack BRCA mutations. Recent studies have shown that EZH2 inhibitors can increase the sensitivity of wild-type BRCA cells to PARP inhibitors. We designed a series of dual PARP and EZH2 inhibitors, and the most promising compound, 5a, showed good inhibitory activity against PARP-1 and EZH2 and good inhibitory effects on MDA-MB-231 (IC50 = 2.63 μM) and MDA-MB-468 (IC50 = 0.41 μM) cells with wild-type BRCA. Compared with that of olaparib, the growth inhibitory activities against these two cell types increased by approximately 15- and 80-fold, respectively, which was even more effective than the combination of olaparib and tazemetostat/GSK126. 5a can induce autophagy death of tumor cells and cause less damage to normal cells. Therefore, 5a, as a first-in-class dual PARP and EZH2 inhibitor, is a potential anticancer drug candidate for the treatment of TNBC.

SUBSTITUTED INDOLE MCL-1 INHIBITORS

The present disclosure provides for compounds that inhibit the activity of an anti- apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present disclosure also provides for pharmaceutical compositions as well as methods for using co

SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS

The present invention relates to substituted 6,5 -fused bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.